Tenderwize
Retour à la recherche

Open House Discount Agreements for Colecalciferol (Non-RX) Prescription Products According to Annex 1 AM-RL G-BA, ATC A11CC05

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 05, 2027 · 128 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Colecalciferol, non RX, ausschließlich nach Anlage 1 AM-RL G-BA verordnungsfähige Produkte, ATC A11CC05

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

Open-house agreements may be automatically terminated if other discount agreements for Colecalciferol are concluded in...

No minimum volume or revenue guarantee; actual sales depend on prescription behavior.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of Colecalciferol (Vitamin D3) products (non-RX, prescription products according to Annex 1 AM-RL G-BA, ATC A11CC05)
  • Non-exclusive discount agreements under § 130a Abs. 8 SGB V with AOK Bayern
Afficher le résumé complet

Open-house model for non-exclusive discount agreements on Colecalciferol (non-RX) products for AOK Bayern. All qualified pharmaceutical companies can join. Contracts run from 01/03/2025 to 28/02/2027. No competitive selection; contracts are awarded to all interested and eligible participants.

Risques

Open-house agreements may be automatically terminated if other discount agreements for Colecalciferol are concluded in...

No minimum volume or revenue guarantee; actual sales depend on prescription behavior.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible

Administrative

  • Submission of signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submission of signed contract and appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Discount Agreements for Colecalciferol (Non-RX) Prescription Products According to Annex 1 AM-RL G-BA, ATC A11CC05

Non-exclusive discount agreements for Colecalciferol (Vitamin D3) products, non-RX, prescription products according to Annex 1 AM-RL G-BA. Supply of pharmaceutical products under § 130a Abs. 8 SGB V. Any pharmaceutical company meeting eligibility can join. Contracts are identical and non-negotiable.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 05, 2027

Détails de la procédure

Date de publication
16 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
33054-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30